Diagnostic Evaluation and Management of Marfan Syndrome

Essential Diagnostic Evaluation

The American College of Medical Genetics and Genomics recommends a comprehensive physical examination focusing on skeletal features, including wrist and thumb sign, pectus carinatum or excavatum, hindfoot deformity, arm span-to-height ratio, and reduced upper-to-lower segment ratio, to aid in the diagnosis of Marfan syndrome 1, 2
A detailed family history of aortic disease or sudden death is crucial in diagnosing Marfan syndrome, with a positive family history significantly lowering the diagnostic threshold 1, 2
Echocardiogram is essential to evaluate for aortic root dilatation, with a critical threshold of aortic root Z-score >2 being diagnostic when combined with ectopia lentis or FBN1 mutation 1, 2
A dilated eye examination is necessary to assess for ectopia lentis, which is a major diagnostic criterion for Marfan syndrome 1, 2, 4, 5

The American Heart Association recommends annual echocardiogram if the aortic root is dilated but <4.5 cm in adults, with initiation of beta-blocker therapy to slow aortic growth 1, 2
If the aortic root is >4.5 cm or growing >0.5 cm/year, echocardiogram should be performed every 6 months, with beta-blocker therapy at maximum tolerated dose and urgent cardiothoracic surgery referral for consideration of prophylactic repair 1, 2
The American College of Cardiology recommends aggressive blood pressure control with target <120/80 mmHg and initiation of beta-blocker therapy to reduce hemodynamic stress on the aortic wall 2

Loeys-Dietz syndrome should be considered in the differential diagnosis, with key distinguishing features including bifid uvula, craniosynostosis, arterial tortuosity, and characteristic facial features 6, 4
Hypermobile Ehlers-Danlos syndrome is another differential diagnosis, with distinguishing features including Beighton score ≥5/9, soft velvety skin, easy bruising, chronic pain, and functional GI disorders 2, 5
Vascular Ehlers-Danlos syndrome (Type IV) is a life-threatening condition requiring immediate genetic confirmation with COL3A1 testing, with a median survival of only 48-51 years and avoidance of invasive catheterization due to arterial fragility 7